News

Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, announced the completion of an oversubscribed $175 million…
Read More...

Acasti Pharma Inc. announces the following patent notifications and awards relating to the Company’s three lead drug candidates: The European Patent Office has provided notice of…
Read More...

Pfizer Inc. announced an agreement with UNICEF to supply up to 4 million treatment courses of its COVID-19 oral treatment, PAXLOVID (nirmatrelvir tablets and ritonavir tablets), to 95…
Read More...

Proscia, a leader in digital and computational pathology solutions, and Visiopharm, a world leader in AI-driven precision pathology software, today announced a strategic partnership to…
Read More...

Sen-Jam Pharmaceutical, an innovative life sciences company developing a portfolio of revolutionary anti-inflammatories by repurposing existing molecules for novel combination therapy,…
Read More...

Merck announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as a single agent for the treatment of patients with advanced…
Read More...

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. and its affiliates, has reached an agreement with the Attorney General of Rhode Island that settles the…
Read More...

Wockhardt UK announced a collaboration with Serum Life Sciences UK, a subsidiary of Serum Institute of India, the world’s largest vaccine manufacturer, to deliver a global vaccine…
Read More...

NeuroSense Therapeutics Ltd. announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pharmacokinetic study of PrimeC in healthy adult…
Read More...

Saniona a clinical stage biopharmaceutical company focused on rare diseases, today announced that its ongoing ion channel research collaboration with Boehringer Ingelheim has advanced …
Read More...

NICE has published final draft guidance recommending elosulfase alfa (also called Vimizin and made by BioMarin) for routine use in the NHS for the treatment of mucopolysaccharidosis…
Read More...

Bristol Myers Squibb announced that Opdualag (nivolumab and relatlimab-rmbw), a new,  first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as a single…
Read More...

Centogene N.V. a commercial-stage company focused on generating data-driven insights to diagnose, understand, and treat rare diseases, announced an expansion of the Company’s data…
Read More...

On March 18, 2022, Lynk Pharmaceuticals Co., Ltd. and Simcere announced a strategic partnership to develop and commercialize a highly selective JAK1 inhibitor LNK01001 in China.…
Read More...

Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, and Brookline Capital…
Read More...

Cerveau Technologies, Inc. announced a research collaboration agreement with Roche Products Limited (Roche), on the use of Cerveau’s MK-6240, an investigational imaging agent, in…
Read More...

Moderna, Inc. announced that the first participant has been dosed in the Phase 2 study of the Company's Omicron-specific bivalent booster candidate (mRNA-1273.214), which combines…
Read More...

Erasca, Inc. a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers,…
Read More...

Aeterna Zentaris Inc. a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, announced it has expanded…
Read More...

Intellia Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia’s ex vivo investigational T cell receptor (TCR)-T…
Read More...